Differential diagnosis of idiopathic pulmonary fibrosis

Cover Page

Cite item

Full Text

Abstract

The review is devoted to the urgent problem of modern pulmonology: the differential diagnosis of idiopathic pulmonary fibrosis (ILF). ILF occupies a special place among many interstitial lung diseases for a number of reasons: 1) it is a deadly disease; 2) early diagnosis and adequate antifibrotic therapy significantly extend the life expectancy of patients; 3) anti-inflammatory drugs (corticosteroids) and cytostatics with ILF that are widely used in other forms of interstitial lung diseases are ineffective and accelerate the progression of the process; 4) the commonality of the main clinical signs (increasing respiratory failure) of various interstitial lung diseases. The list of respiratory diseases with which ILF should be differentiated is huge, and if with diffuse lung lesions of a known nature (disseminated pulmonary tuberculosis, pneumoconiosis, etc.) with a certain experience/qualification, the diagnosis is relatively simple, then the isolation of ILF from the group of idiopathic interstitial pneumonias always represents certain difficulties. The main methods used in the diagnosis of ILF are summarized taking into account current international and national recommendations.

About the authors

E. I. Shmelev

Central Research Institute of Tuberculosis

Author for correspondence.
Email: eishmelev@mail.ru
ORCID iD: 0000-0002-1908-5601

д.м.н., проф., засл. деятель науки РФ, зав. отд. дифференциальной диагностики туберкулеза легких и экстракорпоральных методов лечения

Russian Federation, Moscow

A. E. Ergeshov

Central Research Institute of Tuberculosis

Email: eishmelev@mail.ru

д.м.н., проф., дир. 

 
Russian Federation, Moscow

V. Ya. Gergert

Central Research Institute of Tuberculosis

Email: eishmelev@mail.ru

д.м.н., проф. зав. отд. иммунологии

Russian Federation, Moscow

References

  1. Raghu G, Collard HR, Egan JJ, et al. An Official ATS/ERS/JRS/ALAT Statement: Idiopathic Pulmonory Fibrosis: Evidence-based Guidelines for Diagnosis fnd management. Am J Respir Crit Care Med. 2011;183:788-824. doi: 10.1164/rccm.2009-040gl
  2. Raghu G, et al. Am J Respir Crit Care Med. 2018 Sep 1;198(5):44-68. doi: 10.1164/rccm.201807-1255ST
  3. Oldham JM, Collard HR. Comorbid Conditions in Idiopathic Pulmonary Fibrosis: Recognition and Management. Front Med (Lausanne). 2017;4:123. doi: 10.3389/fmed.2017.00123
  4. Baumgartner KB, Samet JM, Stidley CA, et al. Cigarette smoking: a risk factor for idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 1997;155(1):242-8. doi: 10.1164/ajrccm.155.1.9001319
  5. Ryerson CJ, Hartman T, Elicker BM, et al. Clinical features and outcomes in combined pulmonary fibrosis and emphysema in idiopathic pulmonary fibrosis. Chest. 2013;144(1):234-40. doi: 10.1378/chest.12-2403
  6. Kurashima K, Takayanagi N, Tsuchiya N, et al. The effect of emphysema on lung function and survival in patients with idiopathic pulmonary fibrosis. Respirology. 2010;15(5):843-8. doi: 10.1111/j.1440-1843.2010.01778.x
  7. Qaseem A, Wilt TJ, Weinberger SE, et al. Diagnosis and management of stable chronic obstructive pulmonary disease: a clinical practice guideline update from the American College of Physicians, American College of Chest Physicians, American Thoracic Society, and European Respiratory Society. Ann Intern Med. 2011;155(3):179-91. doi: 10.7326/0003-4819-155-3-201108020-00008
  8. Cottin V, Nunes H, Brillet PY, et al. Combined pulmonary fibrosis and emphysema: a distinct underrecognised entity. Eur Respir J. 2005;26(4):586-93. doi: 10.1183/09031936.05.00021005
  9. Cottin V, Hansell DM, et al. Effect of emphysema extent on serial lung function in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2017. doi: 10.1164/rccm.201612-2492oc
  10. Hubbard R, Venn A, Lewis S, Britton J. Lung cancer and cryptogenic fibrosing alveolitis. A population-based cohort study. Am J Respir Crit Care Med. 2000;161(1):5-8. doi: 10.1164/ajrccm.161.1.9906062
  11. Park J, Kim DS, Shim TS, et al. Lung cancer in patients with idiopathic pulmonary fibrosis. Eur Respir J. 2001;17(6):1216-9. doi: 10.1183/09031936.01.99055301
  12. Le Jeune I, Gribbin J, West J, et al. The incidence of cancer in patients with idiopathic pulmonary fibrosis and sarcoidosis in the UK. Respir Med. 2007;101(12):2534-40. doi: 10.1016/j.rmed.2007.07.012
  13. Ozawa Y, Suda T, Naito T, et al. Cumulative incidence of and predictive factors for lung cancer in IPF. Respirology. 2009;14(5):723-8. doi: 10.1111/j.1440-1843.2009.01547.x
  14. Matsushita H, Tanaka S, Saiki Y, et al. Lung cancer associated with usual interstitial pneumonia. Pathol Int. 1995;45(12):925-32. doi: 10.1111/j.1440-1827.1995.tb03417.x
  15. Tomassetti S, Gurioli C, Ryu JH, et al. The impact of lung cancer on survival of idiopathic pulmonary fibrosis. Chest. 2015;147(1):157-64. doi: 10.1378/chest.14-0359
  16. Usui K, Tanai C, Tanaka Y, et al. The prevalence of pulmonary fibrosis combined with emphysema in patients with lung cancer. Respirology. 2011;16(2):326-31. doi: 10.1111/j.1440-1843.2010.01907.x
  17. Koo HJ, Do KH, Lee JB, et al. Lung cancer in combined pulmonary fibrosis and emphysema: a systematic review and meta-analysis. PLoS One. 2016;11(9):e0161437. doi: 10.1371/journal.pone.0161437
  18. Karampitsakos T, Tzilas V, Tringidou R, et al. Lung cancer in patients with idiopathic pulmonary fibrosis. Pulm Pharmacol Ther. 2017. doi: 10.1016/j.pupt.2017.03.016
  19. Gille T, Didier M, Boubaya M, et al. Obstructive sleep apnoea and related comorbidities in incident idiopathic pulmonary fibrosis. Eur Respir J. 2017;49(6). doi: 10.1183/13993003.01934-2016
  20. Mermigkis C, Chapman J, Golish J, et al. Sleep-related breathing disorders in patients with idiopathic pulmonary fibrosis. Lung. 2007;185(3):173-8. doi: 10.1007/s00408-007-9004-3
  21. Kolilekas L, Manali E, Vlami KA, et al. Sleep oxygen desaturation predicts survival in idiopathic pulmonary fibrosis. J Clin Sleep Med. 2013;9(6):593-601. doi: 10.5664/jcsm.2758
  22. Song JW, Song JK, Kim DS. Echocardiography and brain natriuretic peptide as prognostic indicators in idiopathic pulmonary fibrosis. Respir Med. 2009;103(2):180-6. doi: 10.1016/j.rmed.2008.11.012
  23. Mermigkis C, Bouloukaki I, Antoniou K, et al. Obstructive sleep apnea should be treated in patients with idiopathic pulmonary fibrosis. Sleep Breath. 2015;19(1):385-91. doi: 10.1007/s11325-014-1033-6
  24. Miyake Y, Sasaki S, Yokoyama T, et al. Case-control study of medical history and idiopathic pulmonary fibrosis in Japan. Respirology. 2005;10(4):504-9. doi: 10.1111/j.1440-1843.2005.00742.x
  25. King ChS, Nathan SD. Idiopathic pulmonary fibrosis: effects and optimal management of comorbidities. Lancet Resp Med. 2017;5(1):72-84. doi: 10.1016/S2213-2600(16)30222-3
  26. Hubbard RB, Smith C, Le Jeune I, et al. The association between idiopathic pulmonary fibrosis and vascular disease: a population-based study. Am J Respir Crit Care Med. 2008;178(12):1257-61. doi: 10.1164/rccm.200805-725oc
  27. Kim WY, Mok Y, Kim GW, et al. Association between idiopathic pulmonary fibrosis and coronary artery disease: a case-control study and cohort analysis. Sarcoidosis Vasc Diffuse Lung Dis. 2015;31(4): 289-96.
  28. Nathan SD, Basavaraj A, Reichner C, et al. Prevalence and impact of coronary artery disease in idiopathic pulmonary fibrosis. Respir Med. 2010;104(7):1035-41. doi: 10.1016/j.rmed.2010.02.008
  29. Galie N, Humbert M, Vachiery JL, et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: the Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Heart J. 2016;37(1):67-119. doi: 10.1093/eurheartj/ehv317
  30. Collard HR, Ward AJ, Lanes S, et al. Burden of illness in idiopathic pulmonary fibrosis. J Med Econ. 2012;15(5):829-35. doi: 10.3111/13696998.2012.680553
  31. Nadrous HF, Pellikka PA, Krowka MJ, et al. Pulmonary hypertension in patients with idiopathic pulmonary fibrosis. Chest. 2005;128(4):2393-9. doi: 10.1378/chest.128.4.2393
  32. Lederer DJ, Arcasoy SM, Wilt JS, et al. Six-minute-walk distance predicts waiting list survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2006;174(6):659-64. doi: 10. 1164/rccm.200604-520oc
  33. Haddad F, Spruijt OA, Denault AY, et al. Right heart score for predicting outcome in idiopathic, familial or drug and toxin associated pulmonary arterial hypertension. J Am Coll Cardiol Imaging. 2015;8:627-38.
  34. Nathan SD, Shlobin OA, Ahmad S, et al. Pulmonary hypertension and pulmonary function testing in idiopathic pulmonary fibrosis. Chest. 2007;131(3):657-63. doi: 10.1378/chest.06-2485
  35. Rivera-Lebron BN, Forfia PR, Kreider M, et al. Echocardiographic and hemodynamic predictors of mortality in idiopathic pulmonary fibrosis. Chest. 2013;144(2):564-70. doi: 10.1378/chest.12-2298
  36. Gribbin J, Hubbard R, Smith C. Role of diabetes mellitus and gastro-oesophageal reflux in the aetiology of idiopathic pulmonary fibrosis. Respir Med. 2009;103(6):927-31. doi: 10.1016/j.rmed.2008.11.001
  37. Ryerson CJ, Abbritti M, Ley B, et al. Cough predicts prognosis in idiopathic pulmonary fibrosis. Respirology. 2011;16(6):969-75. doi: 10.1111/j.1440-1843.2011.01996.x
  38. Raghu G, Freudenberger TD, Yang S, et al. High prevalence of abnormal acid gastro-oesophageal reflux in idiopathic pulmonary fibrosis. Eur Respir J. 2006;27(1):136-42. doi: 10.1183/09031936.06.00037005
  39. Savarino E, Carbone R, Marabotto E, et al. Gastro-oesophageal reflux and gastric aspiration in idiopathic pulmonary fibrosis patients. Eur Respir J. 2013;42(5):1322-31. doi: 10.1183/09031936.00101212
  40. Gavini S, Finn RT, Lo WK, et al. Idiopathic pulmonary fibrosis is associated with increased impedance measures of reflux compared to non-fibrotic disease among pre-lung transplant patients. Neurogastroenterol Motil. 2015;27(9):1326-32. doi: 10.1111/nmo.12627
  41. Noth I, Zangan SM, Soares RV, et al. Prevalence of hiatal hernia by blinded multidetector CT in patients with idiopathic pulmonary fibrosis. Eur Respir J. 2012; 39(2):344-51. doi: 10.1183/09031936.00099910
  42. Tossier C, Dupin C, Plantier L, et al. Hiatal hernia on thoracic computed tomography in pulmonary fibrosis. Eur Respir J. 2016;48(3):833-42. doi: 10.1183/13993003.01796-2015
  43. Sawin CT, Castelli WP, Hershman JM, et al. The aging thyroid. Thyroid deficiency in the Framingham Study. Arch Intern Med. 1985;145(8):1386-8. doi: 10.1001/archinte.1985.00360080056006
  44. Vanderpump MP, Tunbridge WM, French JM, et al. The incidence of thyroid disorders in the community: a twenty-year follow-up of the Whickham Survey. Clin Endocrinol (Oxf). 1995;43(1):55-68. doi: 10.1111/j.1365-2265.1995.tb01894.x
  45. Garber JR, Cobin RH, Gharib H, et al. Clinical practice guidelines for hypothyroidism in adults: cosponsored by the American Association of Clinical Endocrinologists and the American Thyroid Association. Endocr Pract. 2012;18(6):988-1028. doi: 10.4158/ep12280.gl
  46. Akhtar AA, Ali MA, Smith RP. Depression in patients with idiopathic pulmonary fibrosis. Chron Respir Dis. 2013;10(3):127-33. doi: 10.1177/1479972313493098
  47. Holland AE, Fiore JF Jr, Bell EC, et al. Dyspnoea and comorbidity contribute to anxiety and depression in interstitial lung disease. Respirology. 2014;19(8):1215-21. doi: 10.1111/resp.12360
  48. Lynch DA, et al. Diagnostic criteria for idiopathic pulmonary fibrosis: a Fleischner Society White Paper. Lancet Respir Med. 2018 Feb;6(2):138-53. doi: 10.1016/s2213-2600(17)30433-2
  49. Wolters PJ, et al. Time for a Change: Is Idiopathic Pulmonary Fibrosis Still Idiopathic and Only Fibrotic? Lancet Respir Med. 2018;6 (2):154-60. doi: 10.1016/s2213-2600(18)30007-9
  50. Wells AU, Ward S Pulmanary Function tests in Idiopathic Pulmonory Fibrosis. In book: Idiopathic Pulmonory Fibrosis:A Comprehancive Clinical Guide. Springer Science. N York, 2014;p. 103-21. doi: 10.1007/978-1-62703-682-5_6
  51. Илькович М.М. Интерстициальные заболевания легких: рассуждения на актуальную тему. Части 1 и 2. Болезни органов дыхания (Прил. Consilium Medicum). 2014;с. 4-9 [Ilkovich MM. Interstitial lung disease: reasoning on the current topic. Parts 1 and 2. Diseases of the Respiratory System (Suppl. Consilium Medicum). 2014;p. 4-9 (In Russ.)].
  52. Шмелев Е.И. Идиопатический легочный фиброз – современное состояние проблемы. Терапевтический архив. 2016;88(12):103-8 [Shmelev EI. Idiopathic pulmonary fibrosis is the current state of the problem. Therapeutic Archive. 2016;88(12):103-8 (In Russ.)]. doi: 10.26442/2075-1753_20.3.30-34
  53. Seibold MA, Wise AL, Speer MC, et al. A common MUC5B promoter polymorphism and pulmonary fibrosis. N Engl J Med. 2011;364:1503-12. doi: 10.1056/nejmoa1013660
  54. Mushiroda T, Wattanapokayakit S, Takahashi A, et al. A genome-wide association study identifi es an association of a common variant in TERT with susceptibility to idiopathic pulmonary fi brosis. J Med Genet. 2008;45:654-6. doi: 10.1136/jmg.2008.057356
  55. Collard HR, Moore BB, Flaherty KR, et al. Acute exacerbation of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2007;176(7):636-43.
  56. Lee JS, Collard HR. Acute exacerbation of idiopathic pulmonary fibrosis. Idiopathic Pulmonory Fibrosis: A Comprehancive Clinical Guide. Springer Science. N York, 2014;p. 349-58.

Supplementary files

Supplementary Files
Action
1. JATS XML

Copyright (c) 2020 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 
 


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies